In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT +0.33%), Johnson & Johnson (JNJ +0.52%), Sanofi (SNY +1.00%), Pfizer (PFE +0.97%), and Merck (MRK +1.86%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
Big Pharma's New Battle for Eyeballs
By Brenton Flynn – Jan 4, 2013 at 6:30PM
Who's buying Bausch & Lomb?